Patient with history of atrial fibrillation: 1 trials - CAPRAF (Tveit)
Patients without history of AF (primary prevention): 1 trials - CHARM (AF ancillary study)
1 trials - SYNTAX (unprotected left main sub group)
1 trials - SCOPE (diabetic subgroup)
All type of patients: 8 trials - ARCH-J - CHARM-Added - CHARM-Alternative - Mitrovic et al. - SPICE - RESOLVD association - STRETCH - RESOLVD (candesartan alone)
Patients already receiving ACE inhibitor: 1 trials - CHARM-Added
Patients intolerant to ACE inhibitors: 2 trials - CHARM-Alternative - SPICE
Patients previously untreated with ACE inhibitors: 1 trials - ARCH-J
Patients with preserved-LVEF heart failure : 1 trials - CHARM preserved
All diseases requiring ACEi (HF, CHD, HT,...): 8 trials - HIJ-CREATE - HIJ-CREATE - CASE-J - Takahashi - E-COST - E-COST-R - ALPINE - SCOPE
All type of patient: 8 trials - HIJ-CREATE - CASE-J - Takahashi - E-COST - E-COST-R - ALPINE - SCOPE - HSCS
Nephropathy: 2 trials - Takahashi - E-COST-R
Patients undergoing dialysis : 2 trials - Suzuki et al - Takahashi et al
Patients with additional risk factor: 1 trials - CASE-J
Patients with cardiovascular disease: 1 trials - HIJ-CREATE
Subjects with pre-hypertension: 1 trials - TROPHY
Uncomplicated hypertension: 2 trials - E-COST - ALPINE
8 trials - HIJ-CREATE - CASE-J - Takahashi - TROPHY - E-COST - E-COST-R - ALPINE - SCOPE
2 trials - Andreozzi (200 vs 100) - Andreozzi (desmin SC vs 100)
Elective hip replacement: 3 trials - Ericksson - REVASC - Eriksson
Orthopedic surgery: 3 trials - Ericksson - REVASC - Eriksson
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
